Stockwatch: Should A Biotech’s First Product Be Out-Licensed Or Self-Marketed?
The Binary Biotech Business Development Decision
The licensing or self-commercialization decision can be important for the success of a biotech company, but do other more fundamental factors concerning the drug dictate a company’s success?
You may also be interested in...
Schizophrenia drug licensed from Takeda missed Phase II endpoint for negative symptoms, but hits secondary cognition endpoints. Neurocrine plans to further study compound for cognitive benefits.
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
The FDA’s rejection of Acadia’s label expansion into a broader patient population for its only approved drug resulted in an aggrieved reaction. Better disclosure from both sides would have helped.